Abstract 1612P
Background
Patient centred outcome measures (PCOMs) are increasingly used to structure proactive symptom assessment and help centre care around the specific needs of the patient. This study aimed to review the use of PCOMs as part of the routine care of inpatients reviewed by the integrated palliative care team in a specialist cancer centre.
Methods
Anonymised electronic palliative care PCOM data were retrieved for inpatients between 7/4/2021 to 31/01/2023, including Integrated Palliative Outcome Scale (IPOS), ECOG performance status, Australian Karnofsky Performance Status (AKPS) and Phase of Illness (POI). Descriptive statistics were used to define the complexity of palliative care needs based on IPOS, PS and POI. The effectiveness of the integrated palliative care service was evaluated by examining the difference between PCOM at initial and follow up assessment.
Results
Digital PCOM records for 1115 episodes of inpatient care were included, of which 391 had follow up data. On initial assessment 63% (703) patients had ECOG PS of 3 or 4 and 77% (864) had AKPS of less than 70. The most prevalent physical symptoms were weakness (84%, 1265), pain (80.7%, 1215), and poor mobility (72.3%, 1089). The most prevalent psychosocial symptom was family or friends feeling anxious or worried (85.8%, 1292). 83% (1250) had at least one palliative care need of severe or overwhelming intensity on initial assessment. 67.5% (753) were in an unstable POI on initial assessment, requiring urgent input. On follow up 92% (328) patients were in a stable, deteriorating or dying POI with no change to the care plan required. In patients with initial moderate to overwhelming symptoms, pain improved in 74%, nausea improved in 84%, vomiting improved in 93%, and constipation improved in 68% at follow up.
Conclusions
The high prevalence of physical and psychosocial symptoms demonstrates the complexity of needs and provides evidence of the requirement for integration of specialist palliative care services in cancer centres. The improvement in symptom scores between initial and follow up assessment demonstrates the effectiveness of integrated palliative care for cancer centre inpatients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05